Salvatore La Rosa

Dr. Salvatore La Rosa

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2017 in Genome Medicine
Verified
Journal Article
Open access
PDF file
PDPatricia A. Deverka
Patricia A. Deverka
MMMary A. Majumder
Mary A. Majumder
AVAngela G. Villanueva
Angela G. Villanueva
MAMargaret Anderson
Margaret Anderson
ABAnnette C. Bakker
Annette C. Bakker
AMAmy Mcguire
Amy Mcguire
National and international public–private partnerships, consortia, and government initiatives are underway to collect and share genomic, personal, and healthcare data on a massive scale. Ideally, these efforts will contribute to the creation of a medical information commons (MIC), a comprehensive data resource that is widely available for both research and clinical uses. Stakeholder participation is essential in clarifying goals, deepening understanding of areas of complexity, and addressing long-standing policy concerns such as privacy and security and data ownership. This article describes eight core principles proposed by a diverse group of expert stakeholders to guide the formation of a successful, sustainable MIC. These principles promote formation of an ethically sound, inclusive, participant-centric MIC and provide a framework for advancing the policy response to data-sharing opportunities and challenges.

26 April 2018 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
RARobert Allaway
Robert Allaway
SGSara JC Gosline
Sara JC Gosline
Salvatore La RosaSalvatore La Rosa
Salvatore La Rosa
PKPamela Knight
Pamela Knight
ABAnnette Bakker
Annette Bakker
LLLu Q. Le
Lu Q. Le
Cutaneous neurofibromas (cNF) are a nearly ubiquitous symptom of neurofibromatosis type 1 (NF1), a disorder with a broad phenotypic spectrum caused by germline mutation of the neurofibromatosis type 1 tumour suppressor gene (NF1). Symptoms of NF1 can include learning disabilities, bone abnormalities and predisposition to tumours such as cNFs, plexiform neurofibromas, malignant peripheral nerve sheath tumours and optic nerve tumours. There are no therapies currently approved for cNFs aside from elective surgery, and the molecular aetiology of cNF remains relatively uncharacterised. Furthermore, whereas the biallelic inactivation of NF1 in neoplastic Schwann cells is critical for cNF formation, it is still unclear which additional genetic, transcriptional, epigenetic, microenvironmental or endocrine changes are important. Significant inroads have been made into cNF understanding, including NF1 genotype–phenotype correlations in NF1 microdeletion patients, the identification of recurring somatic mutations, studies of cNF-invading mast cells and macrophages, and clinical trials of putative therapeutic targets such as mTOR, MEK and c-KIT. Despite these advances, several gaps remain in our knowledge of the associated pathogenesis, which is further hampered by a lack of translationally relevant animal models. Some of these questions may be addressed in part by the adoption of genomic analysis techniques. Understanding the aetiology of cNF at the genomic level may assist in the development of new therapies for cNF, and may also contribute to a greater understanding of NF1/RAS signalling in cancers beyond those associated with NF1. Here, we summarise the present understanding of cNF biology, including the pathogenesis, mutational landscape, contribution of the tumour microenvironment and endocrine signalling, and the historical and current state of clinical trials for cNF. We also highlight open access data resources and potential avenues for future research that leverage recently developed genomics-based methods in cancer research.

1 July 2009 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
SHSimon N. Haydar
Simon N. Haydar
CGChiara Ghiron
Chiara Ghiron
LBLaura Bettinetti
Laura Bettinetti
HBHendrick Bothmann
Hendrick Bothmann
TCThomas A. Comery
Thomas A. Comery
RZRiccardo Zanaletti
Riccardo Zanaletti

13 June 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
T,The Synodos for NF2 Consortium ,
The Synodos for NF2 Consortium ,
RARobert Allaway
Robert Allaway
SASteve P. Angus
Steve P. Angus
RBRoberta L. Beauchamp
Roberta L. Beauchamp
JBJaishri O. Blakeley
Jaishri O. Blakeley
WZWen-Ning Zhao
Wen-Ning Zhao
Neurofibromatosis 2 (NF2) is a rare tumor suppressor syndrome that manifests with multiple schwannomas and meningiomas. There are no effective drug therapies for these benign tumors and conventional therapies have limited efficacy. Various model systems have been created and several drug targets have been implicated in NF2-driven tumorigenesis based on known effects of the absence of merlin, the product of the NF2 gene. We tested priority compounds based on known biology with traditional dose-concentration studies in meningioma and schwann cell systems. Concurrently, we studied functional kinome and gene expression in these cells pre- and post-treatment to determine merlin deficient molecular phenotypes. Cell viability results showed that three agents (GSK2126458, Panobinostat, CUDC-907) had the greatest activity across schwannoma and meningioma cell systems, but merlin status did not significantly influence response. In vivo, drug effect was tumor specific with meningioma, but not schwannoma, showing response to GSK2126458 and Panobinostat. In culture, changes in both the transcriptome and kinome in response to treatment clustered predominantly based on tumor type. However, there were differences in both gene expression and functional kinome at baseline between meningioma and schwannoma cell systems that may form the basis for future selective therapies. This work has created an openly accessible resource (www.synapse.org/SynodosNF2) of fully characterized isogenic schwannoma and meningioma cell systems as well as a rich data source of kinome and transcriptome data from these assay systems before and after treatment that enables single and combination drug discovery based on molecular phenotype.

30 April 2003 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
CGColin L. Gibson
Colin L. Gibson
Salvatore La RosaSalvatore La Rosa
Salvatore La Rosa
CSColin J. Suckling
Colin J. Suckling
The development of a versatile solid phase synthesis of bicyclic polyaza heterocycles including pteridines, purines, and deazapurines is described. The strategy comprises the linking of a pre-formed pyrimidine through a thioether at the 2 or 4 position to a polystyrene resin, the cyclisation of the second ring, and the direct or oxidative cleavage of the product from the resin by nucleophilic substitution. This provides not only for substituent variation in the second ring, but also for variation at the site of cleavage. Limitations in the scope of the methodology are set by the intrinsic reactivity of pyrimidinyl 2- or 4-thioethers which, whilst undergoing ready nitration at C5, are surprisingly difficult to alkylate and acylate.

1 January 2004 in Tetrahedron
Verified
Journal Article
Closed access
CGColin L Gibson
Colin L Gibson
Salvatore La RosaSalvatore La Rosa
Salvatore La Rosa
KOKyuji Ohta
Kyuji Ohta
PBPeter H Boyle
Peter H Boyle
FLFabien Leurquin
Fabien Leurquin
CSColin J. Suckling
Colin J. Suckling